Navigation Links
TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials

ents discontinued treatment for any reason vs. 73 in the placebo arm.

Most of the rashes seen with TMC125 were mild to moderate in severity, occurred within the first few weeks of treatment and resolved with continued TMC125 treatment. Grade 3 or 4 rash occurred in 1 percent of patients in the TMC125 arm and no patients in the placebo arm.

DUET-1 and -2 Study Design

The DUET studies are double-blind, placebo-controlled, international Phase 3 trials designed to assess the efficacy and safety of TMC125 in treatment- experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. Participants were randomized to receive TMC125 200 mg twice daily or placebo, each given in addition to a BR.

In both studies, patient randomization was stratified for enfuvirtide use in the BR (no use, re-use, or first time use), previous darunavir use (used or not), and screening plasma viral load (<30,000 or >=30,000 copies per mL).

Patients with HIV-1 who were eligible for the DUET trials had a viral load of greater than 5,000 copies/mL, were on a stable antiretroviral therapy regimen, and had evidence of at least one NNRTI-resistance-associated mutation, either at screening or from historical resistance tests as well as evidence of three or more primary PI mutations at screening.

TMC125 Expanded Access Program

The expanded access program (EAP) for TMC125 is now open in a number of European countries, Canada and the United States. TMC125 is available to HIV-1 infected adults, at least 18 years old, who have limited treatment options either due to virological failure or intolerance to multiple ARV regimens. Patients must be three-class experienced, having received licensed treatment from each of the three major oral classes of anti-HIV drugs (NRTIs, NNRTIs, and PIs), unable to use currently approved NNRTIs due to resistance and/or intolerance and have received at least two PI-based regimens.

For more about the pro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
5. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
6. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
10. OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014 Reportbuyer.com has ... Global Bone Densitometers Market 2014-2018 ... bone densitometry scan is a special type of X-ray ... bone. It is used primarily to detect osteopenia or ... and the risk of fractures is high. The purpose ...
(Date:7/28/2014)... , July 28, 2014 KaloBios Pharmaceuticals, Inc. ... on the status of the KB001-A development program, including ... KB001-A Collaboration Update ... Sanofi Pasteur to regain all rights to KaloBios, KB001-A ... entered into in 2010 has been terminated. Under that ...
(Date:7/28/2014)... , July 28, 2014  Some 2,500 scientists and ... in Montreal for the largest ... a discipline that draws researchers from fields as far ... as diverse as designing new manufacturing processes to creating ... special time because the United Nations has declared 2014 ...
Breaking Medicine Technology:Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 2All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 3All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 4All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 5All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 6
(Date:7/29/2014)... 2014 The Eleventh Annual Business Plan ... with the $10,000 prize being presented to Ambika Bumb, ... , The 11th Annual Summit was held on June ... can bring innovative products and services for the longevity ... have had such excellent array of young companies enter ...
(Date:7/29/2014)... 2014 Oxnard dentists , Dr. Saj ... Institute in Oxnard and Woodland Hills, Calif., regularly give patients ... been removed due to dental disease. , However, dental implants ... (experts in restoring and replacing teeth) want the public to ... to perform their dental work and of not caring for ...
(Date:7/29/2014)... 29, 2014 "Acceptance, Recognition, and Control ... faced his own demons and wants other men to heed ... partner left. A month later, he had no job, leaving ... When Raymond approached the government for assistance, the emotional disturbance ... counselling program. But this approach didn’t get to the root ...
(Date:7/29/2014)... 2014 Gout was one called “the disease ... proven that last statement essentially moot since many people of ... do not have are the resources to deal with such ... to maintain treatment for it, but the effects of the ... a grinding halt. , Alternative medicine specialist and ...
(Date:7/29/2014)... Oconto Falls, WI (PRWEB) July 29, 2014 ... their third development project, The Cottages at MeadowLands Memory ... the growing population of those suffering from memory loss ... W.M. Enterprises, Inc., has approved the development of Oconto ... memory care. Cara Peterson, GM of The Cottages Investment ...
Breaking Medicine News(10 mins):Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:Oxnard Dental Implant Experts Warn of Infections Around Dental Implants 2Health News:Oxnard Dental Implant Experts Warn of Infections Around Dental Implants 3Health News:Oxnard Dental Implant Experts Warn of Infections Around Dental Implants 4Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 4
... local organizations and,individuals committed to the fight against ... awarded 2009 Cheerios Angel de mi Corazon grants,to ... winning pool of nominations, the,winning grant recipients developed ... excellent resources to help raise,the level of awareness ...
... DIEGO, March 31 CareFusion Corporation, the company that ... Cardinal Health,s clinical and medical products businesses, today filed ... Exchange Commission (SEC) that contains detailed information about the ... filing outlines Cardinal Health,s plan to spin off at ...
... Council R&D Taskforce forum demonstrated that Australian clinical ... increased government support for and community participation in ... championing the 2009 Clinical Trials Honour Roll, designed ... trials in Australia over the past year. , ...
... Presented at 58th Annual Scientific Session of the ... Underused in Eligible Patients with Non-Valvular Atrial Fibrillation ... Boehringer Ingelheim today announced that it plans to ... Fibrillation), a U.S. based registry to evaluate patterns ...
... Ind., March 31 Conseco, Inc. (NYSE: CNO ), reported today ... The changes made to the credit agreement include:, , ... ratio through June 30, 2010 to 32.5%, returning to 30% thereafter; , ... 1.5x through June 30, 2010, returning to 2.0x thereafter; , ...
... shocking information about what lurks beneath the sheets , ... Duquesne, PA ... haven for rest and rejuvenation. But if most people - particularly ... they might think that their bed is more like a litter box ...
Cached Medicine News:Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 3Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 4Health News:CareFusion Corporation Files Form 10 Registration Statement 2Health News:CareFusion Corporation Files Form 10 Registration Statement 3Health News:CareFusion Corporation Files Form 10 Registration Statement 4Health News:CareFusion Corporation Files Form 10 Registration Statement 5Health News:CareFusion Corporation Files Form 10 Registration Statement 6Health News:Australian clinical trials threatened: Jobs and patient access to new treatments at stake 2Health News:Australian clinical trials threatened: Jobs and patient access to new treatments at stake 3Health News:Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation 2Health News:Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation 3Health News:Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation 4Health News:Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation 5Health News:Conseco Closes Amendment to Credit Facility 2Health News:Conseco Closes Amendment to Credit Facility 3Health News:Conseco Closes Amendment to Credit Facility 4Health News:Five Secrets Your Bed Won't Tell You 2Health News:Five Secrets Your Bed Won't Tell You 3Health News:Five Secrets Your Bed Won't Tell You 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: